Nick Abbott
Stock Analyst at Wells Fargo
(0.08)
# 4,159
Out of 4,761 analysts
6
Total ratings
20%
Success rate
-36.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nick Abbott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Assumes: Overweight | $45 → $9 | $14.39 | -37.46% | 1 | Oct 4, 2022 | |
| TCRT Alaunos Therapeutics | Assumes: Overweight | $450 | $1.68 | +26,685.71% | 2 | Oct 4, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $7 → $1.5 | $0.56 | +168.10% | 1 | Oct 4, 2022 | |
| CLLS Cellectis | Downgrades: Equal-Weight | $16 | $1.53 | +945.75% | 1 | Jan 6, 2022 | |
| AFMD Affimed | Maintains: Overweight | $100 → $150 | $1.04 | +14,323.08% | 1 | Mar 24, 2021 |
Zymeworks
Oct 4, 2022
Assumes: Overweight
Price Target: $45 → $9
Current: $14.39
Upside: -37.46%
Alaunos Therapeutics
Oct 4, 2022
Assumes: Overweight
Price Target: $450
Current: $1.68
Upside: +26,685.71%
Adaptimmune Therapeutics
Oct 4, 2022
Maintains: Equal-Weight
Price Target: $7 → $1.5
Current: $0.56
Upside: +168.10%
Cellectis
Jan 6, 2022
Downgrades: Equal-Weight
Price Target: $16
Current: $1.53
Upside: +945.75%
Affimed
Mar 24, 2021
Maintains: Overweight
Price Target: $100 → $150
Current: $1.04
Upside: +14,323.08%